drugset / Trial / NCT07241793
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Phase 2
Recruiting
96 enrolled
Sun Yat-sen University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collabThe Second Affiliated Hospital of Kunming Medical University · collabThe fifth Affiliated Hospital of Guangzhou Medcial University · collabTongji Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, Phase II clinical trial to evaluate the efficacy and safety of Trastuzumab Rezetecan (SHR-A1811) or in combination with Adebrelimab (SHR-1316) for HER2-expressing locally advanced or metastatic urothelial carcinoma (la/mUC).
Timeline
- Start
- 2025-11-20
- Primary completion
- 2028-07-01
- Completion
- 2031-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | — |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | 4.8 mg/kg | — |